AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Top Ranked Income Stocks to Buy for October 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 17th.
Is AbbVie (ABBV) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
by Zacks Equity Research
AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.
Top Ranked Momentum Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th.
Reata Successfully Completes Neuromuscular Disorder Study
by Zacks Equity Research
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
by Zacks Equity Research
J&J (JNJ) comes up with encouraging third-quarter 2019 results.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Top Ranked Income Stocks to Buy for October 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 10th.
J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case
by Zacks Equity Research
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
AbbVie (ABBV) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $74.33, moving -0.44% from the previous trading session.
5 Excellent GARP Picks Based on Discounted PEG
by Urmimala Biswas
While P/E gives an idea of stocks trading at a discount, PEG helps to find stocks with solid future potential.
The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie
Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy
by John Blank
Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?
Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy
by John Blank
Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
5 Dividend Aristocrats to Buy as October Sees a Shaky Start
by Tirthankar Chakraborty
With things looking dicey for the stock market this October, it's prudent to invest in dividend aristocrats for their risk-adjusted returns.
Vertex Enters Into Collaboration With Privately-Held Ribometrix
by Zacks Equity Research
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
Top Ranked Income Stocks to Buy for October 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.
Top Stock Reports for AbbVie, Starbucks & Phillips 66
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie (ABBV), Starbucks (SBUX) and Phillips 66 (PSX).
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $75.73 in the latest trading session, marking a +1.18% move from the prior day.